Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease

被引:199
作者
Papi, A
Romagnoli, M
Baraldo, S
Braccioni, F
Guzzinati, I
Saetta, M
Ciaccia, A
Fabbri, LM
机构
[1] Univ Modena, Dept Pulm Dis, I-41100 Modena, Italy
[2] Univ Ferrara, Res Ctr Asthma, I-44100 Ferrara, Italy
[3] Univ Ferrara, COPD, I-44100 Ferrara, Italy
[4] Univ Padua, Inst Occupat Med, Padua, Italy
关键词
D O I
10.1164/ajrccm.162.5.9910112
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
We investigated the relationship between the reversibility of airflow limitation, the concentration of nitric oxide (NO) in exhaled air, and the inflammatory cells in the sputum of patients with stable chronic obstructive pulmonary disease (COPD). We examined nine normal healthy control subjects and 20 nonatopic patients with COPD. Ten patients had no reversibility of airflow limitation (increase in FEV1 of < 12% and < 200 ml after 200 mug of inhaled salbutamol), and 10 patients had partial reversibility of airflow limitation (increase in FEV1 of < 12% but > 200 ml after 200 mug of inhaled salbutamol). Exhaled NO levels were higher in COPD patients with partial reversibility of airflow limitation than in those with no reversibility of airflow limitation (median 24 [interquartile range 15.3 to 32] ppb versus 8.9 [4.6 to 14.7] ppb; p < 0.01). Compared with healthy control subjects, only COPD patients with partial reversibility of airflow limitation had increased concentrations of sputum eosinophils. We conclude that, in patients with stable COPD, even a partial bronchodilator response to inhaled salbutamol is associated with increased exhaled NO and sputum eosinophilia, suggesting that these patients may have a different response to treatment than do those without reversible airflow limitation.
引用
收藏
页码:1773 / 1777
页数:5
相关论文
共 35 条
[2]  
ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814
[3]   Exhaled nitric oxide: A new lung function test [J].
Barnes, PJ ;
Kharitonov, SA .
THORAX, 1996, 51 (03) :233-237
[4]   ORAL CORTICOSTEROID-THERAPY FOR PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - A METAANALYSIS [J].
CALLAHAN, CM ;
DITTUS, RS ;
KATZ, BP .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (03) :216-223
[5]  
CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
[6]   Corticosteroid reversibility in COPD is related to features of asthma [J].
Chanez, P ;
Vignola, AM ;
OShaugnessy, T ;
Enander, I ;
Li, DC ;
Jeffery, PK ;
Bousquet, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (05) :1529-1534
[7]   Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease [J].
Clini, E ;
Bianchi, L ;
Pagani, M ;
Ambrosino, N .
THORAX, 1998, 53 (10) :881-883
[8]   Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease [J].
Corradi, M ;
Majori, M ;
Cacciani, GC ;
Consigli, GF ;
de'Munari, E ;
Pesci, A .
THORAX, 1999, 54 (07) :572-575
[9]   SPIROMETRY - QUALITY-CONTROL AND REPRODUCIBILITY CRITERIA [J].
CRAPO, RO .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (06) :1212-1213
[10]   Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema [J].
Fujimoto, K ;
Kubo, K ;
Yamamoto, H ;
Yamaguchi, S ;
Matsuzawa, Y .
CHEST, 1999, 115 (03) :697-702